Stamoulis Christiana's most recent trade in Incyte Corp. was a trade of 18,970 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 18,970 | 129,093 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 18,598 | 110,123 (0%) | 0% | 0 | Common Stock | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 5,535 | 5,535 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 1,864 | 47,336 (0%) | 0% | - | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 25,516 | 25,516 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.46 per share. | 15 Jan 2025 | 3,672 | 91,525 (0%) | 0% | 72.5 | 266,073 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 9,039 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Sale of securities on an exchange or to another person at price $ 79.50 per share. | 17 Jul 2024 | 9,039 | 45,472 (0%) | 0% | 79.5 | 718,601 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.74 per share. | 17 Jul 2024 | 9,039 | 54,511 (0%) | 0% | 26.7 | 241,703 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 28,127 | 28,127 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 12,572 | 96,145 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.25 per share. | 15 Jul 2024 | 948 | 95,197 (0%) | 0% | 64.3 | 60,909 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 59.02 per share. | 02 Jul 2024 | 6,870 | 83,573 (0%) | 0% | 59.0 | 405,467 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 4,536 | 4,536 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 1,572 | 45,472 (0%) | 0% | - | Common Stock | |
Incyte Corp. | Stamoulis Christiana | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 7,377 | 89,983 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.84 per share. | 12 Feb 2024 | 387 | 82,606 (0%) | 0% | 57.8 | 22,384 | Common Stock |
Incyte Corp. | Stamoulis Christiana | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 27,668 | 27,668 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 25,682 | 25,682 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 12,246 | 82,993 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.08 per share. | 03 Jul 2023 | 6,073 | 70,747 (0%) | 0% | 62.1 | 377,012 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 4,210 | 4,210 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 1,465 | 43,900 (0%) | 0% | - | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.08 per share. | 13 Feb 2023 | 848 | 76,791 (0%) | 0% | 80.1 | 67,908 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.08 per share. | 13 Feb 2023 | 331 | 76,460 (0%) | 0% | 80.1 | 26,506 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 24,515 | 24,515 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,980 | 77,639 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2022 | 23,221 | 23,221 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2022 | 17,317 | 73,783 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.25 per share. | 02 Jul 2022 | 1,124 | 72,659 (0%) | 0% | 79.3 | 89,077 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 5,293 | 5,293 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 1,565 | 42,435 (0%) | 0% | - | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.76 per share. | 11 Feb 2022 | 846 | 56,616 (0%) | 0% | 66.8 | 56,479 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.76 per share. | 11 Feb 2022 | 331 | 56,285 (0%) | 0% | 66.8 | 22,098 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 15,054 | 15,054 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 14,463 | 57,462 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 2,355 | 42,999 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 379 | 40,644 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2021 | 15,054 | 15,054 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2021 | 7,853 | 40,781 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jul 2021 | 516 | 40,265 (0%) | 0% | 0 | Common Stock | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 5,055 | 5,055 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 1,478 | 40,870 (0%) | 0% | - | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.99 per share. | 11 Feb 2021 | 1,210 | 32,611 (0%) | 0% | 85.0 | 102,838 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 12,743 | 12,743 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 11,522 | 33,821 (0%) | 0% | 0 | Common Stock | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2020 | 1,232 | 22,299 (0%) | 0% | 0 | Common Stock | |
Hologic, Inc. | Christiana Stamoulis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 11,146 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
Hologic, Inc. | Christiana Stamoulis | Director | Sale of securities on an exchange or to another person at price $ 74.00 per share. | 04 Nov 2020 | 11,146 | 39,392 (0%) | 0% | 74 | 824,804 | Common Stock |
Hologic, Inc. | Christiana Stamoulis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.35 per share. | 04 Nov 2020 | 11,146 | 50,538 (0%) | 0% | 22.3 | 249,113 | Common Stock |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2020 | 12,743 | 12,743 | - | - | Employee Stock Option (right to buy) | |
Incyte Corp. | Christiana Stamoulis | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2020 | 6,661 | 21,067 (0%) | 0% | 0 | Common Stock |